Fleebs-Logo
Details werden geladen...

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) | The Manila Times

WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (the 'FDA') has granted Fast Track Designation for modzatinib (ATI-2138) for moderate to severe lichen planus (LP) including oral erosive LP, cutaneous LP, and lichen planopilaris. Aclaris expects to initiate a phased multi-part Phase 2b trial of modzatinib in LP in the fourth quarter of 2026.

Ähnliche Seiten

https://www.finanznachrichten.de/nachrichten-2026-07/69143600-haya-therapeutics-receives-fda-fast-track-designation-for-htx-001-004.htm

HAYA Therapeutics Receives FDA Fast Track Designation for HTX-001

https://www.finanznachrichten.de/nachrichten-2026-07/69143600-haya-therapeutics-receives-fda-fast-track-designation-for-htx-001-004.htm
https://www.manilatimes.net/2026/06/15/tmt-newswire/pr-newswire/halia-therapeutics-receives-fda-fast-track-designation-for-ofirnoflast-ht-6184-in-lower-risk-myelodysplastic-syndromes/2365578

Halia Therapeutics Receives FDA Fast Track Designation for Ofirnoflast (HT-6184) in Lower-Risk Myelodysplastic Syndromes | The Manila Times

https://www.manilatimes.net/2026/06/15/tmt-newswire/pr-newswire/halia-therapeutics-receives-fda-fast-track-designation-for-ofirnoflast-ht-6184-in-lower-risk-myelodysplastic-syndromes/2365578
https://www.manilatimes.net/2026/06/30/tmt-newswire/globenewswire/monopar-therapeutics-receives-fda-rare-pediatric-disease-designation-for-alxn1840-for-the-treatment-of-wilson-disease/2375713

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease | The Manila Times

https://www.manilatimes.net/2026/06/30/tmt-newswire/globenewswire/monopar-therapeutics-receives-fda-rare-pediatric-disease-designation-for-alxn1840-for-the-treatment-of-wilson-disease/2375713
https://www.manilatimes.net/2026/06/29/tmt-newswire/globenewswire/satellos-receives-fda-fast-track-designation-for-sat-3247-for-the-treatment-of-duchenne-muscular-dystrophy/2374735

Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy | The Manila Times

https://www.manilatimes.net/2026/06/29/tmt-newswire/globenewswire/satellos-receives-fda-fast-track-designation-for-sat-3247-for-the-treatment-of-duchenne-muscular-dystrophy/2374735
https://www.manilatimes.net/2026/06/24/tmt-newswire/globenewswire/imbria-pharmaceuticals-receives-fda-orphan-drug-designation-for-ninerafaxstat-for-symptomatic-non-obstructive-hypertrophic-cardiomyopathy/2371889

Imbria Pharmaceuticals Receives FDA Orphan Drug Designation for Ninerafaxstat for Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | The Manila Times

https://www.manilatimes.net/2026/06/24/tmt-newswire/globenewswire/imbria-pharmaceuticals-receives-fda-orphan-drug-designation-for-ninerafaxstat-for-symptomatic-non-obstructive-hypertrophic-cardiomyopathy/2371889
https://www.manilatimes.net/2026/08/05/tmt-newswire/globenewswire/lexeo-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-lx2020-for-the-treatment-of-pkp2-arrhythmogenic-cardiomyopathy/2398808

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy | The Manila Times

https://www.manilatimes.net/2026/08/05/tmt-newswire/globenewswire/lexeo-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-lx2020-for-the-treatment-of-pkp2-arrhythmogenic-cardiomyopathy/2398808